Asunto(s)
Factores de Coagulación Sanguínea/uso terapéutico , Pérdida de Sangre Quirúrgica/prevención & control , Medicina Basada en la Evidencia/normas , Factor VIIa/uso terapéutico , Factor XIII/uso terapéutico , Fibrinógeno/uso terapéutico , Hemostáticos/uso terapéutico , Hemorragia Posoperatoria/tratamiento farmacológico , Factores de Coagulación Sanguínea/efectos adversos , Factores de Coagulación Sanguínea/normas , Consenso , Factor VIIa/efectos adversos , Factor VIIa/normas , Factor XIII/efectos adversos , Factor XIII/normas , Fibrinógeno/efectos adversos , Fibrinógeno/normas , Hemostáticos/efectos adversos , Hemostáticos/normas , Humanos , Hemorragia Posoperatoria/sangre , Hemorragia Posoperatoria/diagnóstico , Proteínas Recombinantes/uso terapéutico , Factores de Riesgo , Resultado del TratamientoRESUMEN
BACKGROUND: Many clinical laboratories use a clotting rate assay according to Clauss for the determination of fibrinogen in citrated plasma. The aim of the present study was to assess the commutability of the current International Standard for fibrinogen (coded 09/264), three commercial fibrinogen standards, and 10 freeze-dried plasma quality control samples from various sources. METHODS: Clotting rate assays according to Clauss were performed on three automated instruments (Sysmex CA1500, STA-Rack Evolution and ACL-Top 700), using three commercial thrombin reagents (Siemens, Stago, and Instrumentation Laboratory). Relationships between the results obtained with the three instruments were determined with 25 fresh-frozen plasma samples obtained from patients. The deviations of the assay results obtained with the freeze-dried samples were compared with the deviations obtained with the fresh-frozen samples, according to approved CLSI guideline C53A. RESULTS: Freezing and thawing had no influence on the assay results. There were significant differences in the mean assay results (fibrinogen, g/L) for the fresh-frozen plasma samples between the three automated instruments: 2.51 (STA-Rack Evolution), 2.25 (ACL-Top 700) and 2.20 (Sysmex CA1500). Similar differences were observed for several freeze-dried plasma samples. Some freeze-dried plasma samples, including the International Standard, were out of the 95% confidence interval for the relationship between STA-Rack Evolution and Sysmex CA1500. CONCLUSIONS: Some freeze-dried plasmas including the international standard for fibrinogen are not commutable among automated instruments for fibrinogen clotting rate assays according to Clauss. Our results have consequences for all interested parties in the traceability chain (WHO, industry, external quality assessment schemes, clinical laboratories).
Asunto(s)
Pruebas de Coagulación Sanguínea/normas , Fibrinógeno/análisis , Control de Calidad , Fibrinógeno/normas , Liofilización , Humanos , Estándares de ReferenciaAsunto(s)
Pruebas de Coagulación Sanguínea/normas , Coagulación Sanguínea/efectos de los fármacos , Coagulantes/normas , Fibrinógeno/normas , Cooperación Internacional , Organización Mundial de la Salud , Humanos , Valor Predictivo de las Pruebas , Control de Calidad , Estándares de Referencia , Reproducibilidad de los ResultadosRESUMEN
PURPOSE: Clinical application of biomarker candidates discovered by proteomic analysis is challenging. The purpose of this study was to standardize preanalytical conditions for measurement of serum levels of fibrinogen alpha C-chain 5.9 kDa fragment (FIC 5.9) and to test the diagnostic value of this peptide for detection of early hepatic fibrosis in patients with hepatitis C virus (HCV)-related chronic hepatitis. EXPERIMENTAL DESIGN: Serum FIC 5.9 levels were measured by a sandwich ELISA. Effects on the serum FIC 5.9 level of temperature, the time between venipuncture and serum separation, and the types of collection tubes used were examined. The diagnostic value of serum FIC 5.9 as an early indicator of hepatic fibrosis due to HCV was then assessed. RESULTS: FIC 5.9 was produced in a time- and temperature-dependent manner after venipuncture. Abnormal FIC 5.9 values were found in 89.5% of FI stage patients. Receiver operating characteristic analyses confirmed the superiority of FIC 5.9 over other conventional markers for early detection of fibrosis. CONCLUSIONS AND CLINICAL RELEVANCE: The serum FIC 5.9 level may be an early indicator of hepatic fibrosis in HCV-related chronic liver diseases. This study provides an example of a pipeline from biomarker discovery by proteome analysis to assay optimization and preliminary clinical validation.
Asunto(s)
Hepacivirus/patogenicidad , Cirrosis Hepática/diagnóstico , Fragmentos de Péptidos/sangre , Adulto , Anciano , Biomarcadores/sangre , Recolección de Muestras de Sangre/instrumentación , Recolección de Muestras de Sangre/métodos , Diagnóstico Precoz , Ensayo de Inmunoadsorción Enzimática/normas , Femenino , Fibrinógeno/normas , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/diagnóstico , Humanos , Cirrosis Hepática/sangre , Cirrosis Hepática/etiología , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/normas , Curva ROC , Valores de Referencia , Temperatura , Factores de TiempoRESUMEN
BACKGROUND: Several methods exist for evaluation of hypocoagulation in patients with perioperative bleeding, e.g. thromboelastography (TEG(®)) and conventional methods (platelet count, aPTT, INR and fibrinogen). Considering the vast experience of conventional methods it is important to investigate how well the methods correspond. METHODS: Sixty surgical patients were included prospectively and blood samples were taken perioperatively. TEG(®) and conventional parameters were analyzed simultaneously. An assessment of coagulopathy, based on a synthesis of the conventional methods, was done by two experienced coagulation specialists, blinded from the results of TEG(®) and from the results of each other. Hypocoagulation, defined by TEG(®) parameters; reaction time (R-time), angle, maximal amplitude (MA) and fibrinolysis, was evaluated according to a commonly used algorithm. RESULTS: To detect a platelet count below 150 × 10(9) L(-1), the sensitivity of TEG was 17% (95% CI, 7-36%) with angle and 25% (95% CI, 11-45%) with MA. The sensitivity to detect fibrinogen below 2 g/L was 11% (95% CI, 3-29%) with angle and 21% with MA (95% CI, 8-43%). To detect aPTT more than 40 s and INR more than 1.2 with R-time, the sensitivity was 19% (95% CI, 8-37%) and 0% (95% CI, 0-69%) respectively. The agreement of the evaluator's assessments of hypocoagulation was 100%, but the agreement with the overall TEG(®) analysis was poor with a sensitivity of 33% and a specificity of 95%. CONCLUSION: The agreement between conventional laboratory tests and TEG is poor, but it remains uncertain which type of coagulation tests that best reflects the actual bleeding risk.
Asunto(s)
Coagulación Sanguínea , Pérdida de Sangre Quirúrgica , Fibrinógeno/análisis , Relación Normalizada Internacional/normas , Tiempo de Tromboplastina Parcial/normas , Recuento de Plaquetas/normas , Tromboelastografía/normas , Adulto , Anciano , Femenino , Fibrinógeno/normas , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Procedimientos Quirúrgicos OperativosRESUMEN
BACKGROUND AND OBJECTIVES: The Mirasol® pathogen reduction technology system for plasma is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study was undertaken to evaluate the possibility of making pathogen reduced cryoprecipitate from riboflavin and UV light- treated plasma that meets the quality requirements specified by UK and European guidelines for untreated cryoprecipitate. MATERIALS AND METHODS: Cryoprecipitate was made from riboflavin and UV light-treated plasma. Plasma units were thawed over a 20 h period at 4°C, and variable centrifugation settings (from 654 g for 2 min to 5316 g for 6 min) were applied to identify the optimal centrifugation condition. Plasma proteins in cryoprecipitate units were characterized on a STA Compact, Diagnostica STAGO and Siemens BCS analyzer. RESULTS: Neither the centrifugation speed or time appeared to have an effect on the quality of the final cryoprecipitate product; however the initial solubilization of the cryoprecipitate product was found to be easier at the lower centrifugation setting (654 g for 2 min). Cryoprecipitate units prepared from Mirasol-treated plasma demonstrated protein levels that were less than levels in untreated products, but were on average 93 IU/unit, 262 mg/unit and 250 IU/unit for FVIII, fibrinogen and von Willebrand ristocetin cofactor activity, respectively. CONCLUSION: Cryoprecipitate products prepared from Mirasol-treated plasma using a centrifugation method contain levels of fibrinogen, FVIII and von Willebrand ristocetin cofactor activity, that meet both the European and UK guidelines for untreated cryoprecipitate. Flexibility in centrifugation conditions should allow blood banks to use their established centrifugation settings to make cryoprecipitate from Mirasol-treated plasma.
Asunto(s)
Factor VIII/aislamiento & purificación , Fibrinógeno/aislamiento & purificación , Fármacos Fotosensibilizantes/farmacología , Plasma/química , Riboflavina/farmacología , Rayos Ultravioleta , Desinfección/métodos , Factor VIII/química , Factor VIII/normas , Fibrinógeno/química , Fibrinógeno/normas , HumanosRESUMEN
BACKGROUND: With buffy coat (BC) processing of whole blood (WB) donations, the preparation of plasma occurs within 24 hours rather than 8 hours of collection. The effect of this change on coagulation factor function in plasma and cryoprecipitate was evaluated during the validation of this production method and with routine production. STUDY DESIGN AND METHODS: Plasma frozen after an overnight hold of WB was prepared via BC or whole blood filtration (WBF) methods and quality control (QC) variables were measured. Additionally, plasma prepared with the BC method was compared to plasma produced using the platelet-rich plasma (PRP) method with an extended plasma factor analysis. Selected plasma factor levels were also measured in both cryoprecipitate and cryosupernatant plasma prepared using the WBF method from plasma frozen on the day of collection or after an overnight hold of WB. RESULTS: When comparing BC plasma to PRP plasma, coagulation factors (F)II, VII, VIII, IX, X, and XI had somewhat lower levels, and fibrinogen and antithrombin levels were elevated. As expected the most sensitive to the prolongation of production time was FVIII with 72 and 78% of the activity of PRP plasma and cryoprecipitate, respectively. However, both still met QC standards. Similarly, products made in routine production show acceptable levels of FVIII. CONCLUSION: Plasma and cryoprecipitate products, prepared using methods in which the plasma is frozen close to 24 hours after collection, meet current quality standards. The longer WB storage time has been implemented into general use in Canada.
Asunto(s)
Eliminación de Componentes Sanguíneos/métodos , Conservación de la Sangre/métodos , Centrifugación , Factor VIII/normas , Fibrinógeno/normas , Plasma , Temperatura , Antitrombinas/análisis , Bancos de Sangre/normas , Factores de Coagulación Sanguínea/análisis , Eliminación de Componentes Sanguíneos/economía , Eliminación de Componentes Sanguíneos/normas , Plaquetas/citología , Colombia Británica , Supervivencia Celular , Criopreservación , Citaféresis/métodos , Citaféresis/normas , Fibrinógeno/análisis , Filtración , Humanos , Procedimientos de Reducción del Leucocitos , Plasma Rico en Plaquetas , Estabilidad Proteica , Factores de TiempoRESUMEN
In a Dutch project for harmonization of fibrinogen assays, the commutability of potential calibrators for fibrinogen was assessed by means of a twin-study design, which is, in essence, a multicentre, split-patient sample, between-field-methods protocol. The study consisted of simultaneous analysis of fresh-frozen patient plasmas and three potential calibrators for fibrinogen by 48 Dutch laboratories forming 24 couples. The state-of-the-art intralaboratory standard deviation was used to assess the commutability of the potential calibrators. The potential calibrators were commutable for the Clauss, but not for the prothrombin time (PT)-derived assays. One potential calibrator was used in an attempt to harmonize fibrinogen assay results in a Dutch field study. The interlaboratory coefficient of variation (CV) of three out of four test samples could be reduced significantly using the common calibrator. The average overall CV for the four test samples was 10.3% using the routine measurements and 7.8% using the common calibrator. Despite the reduction in the overall CV, the bias between Clauss and PT-derived assay results in two coumarin test samples could not be eliminated.
Asunto(s)
Calibración/normas , Fibrinógeno/análisis , Técnicas de Laboratorio Clínico/normas , Fibrinógeno/normas , Humanos , Laboratorios/normas , Países Bajos , Garantía de la Calidad de Atención de Salud , Reproducibilidad de los ResultadosAsunto(s)
Transfusión de Componentes Sanguíneos/efectos adversos , Fibrinógeno/efectos adversos , Fibrinógeno/normas , Virosis/transmisión , Brotes de Enfermedades/prevención & control , Factor VIII , Fibrinógeno/aislamiento & purificación , Fibrinógeno/uso terapéutico , Predicción , Humanos , Teoría de la Probabilidad , Riesgo , Esterilización , Inactivación de VirusRESUMEN
A probabilistic model was used to compare cryoprecipitate to viral inactivated, commercial fibrinogen concentrate to evaluate with regard to the recipient's risk of exposure to an emergent AIDS-like epidemic. In patients who occasionally need a therapeutic dose of fibrinogen, commercial fibrinogen would be marginally safer than cryoprecipitate if the new pathogen were sensitive to inactivation. But there is a potential high risk of exposure if the emerging agent withstands inactivation. In most of the analyzed scenarios, cryoprecipitate is safer than commercial fibrinogen as long as the odds that the new agent is sensitive to inactivation are lower than 1.000 to 1.
Asunto(s)
Transfusión de Componentes Sanguíneos/efectos adversos , Fibrinógeno/efectos adversos , Fibrinógeno/normas , Teoría de la Probabilidad , Virosis/transmisión , Brotes de Enfermedades/prevención & control , Factor VIII , Fibrinógeno/aislamiento & purificación , Fibrinógeno/uso terapéutico , Predicción , Humanos , Riesgo , Esterilización , Inactivación de VirusAsunto(s)
Fibrinógeno/análisis , Fibrinógeno/química , Conservación de la Sangre/métodos , Conservación de la Sangre/normas , Calibración , Técnicas de Laboratorio Clínico/normas , Fibrinógeno/normas , Humanos , Cooperación Internacional , Modelos Estadísticos , Estándares de Referencia , Reproducibilidad de los ResultadosRESUMEN
Several national and local external quality assurance schemes have been developed to improve the plasma fibrinogen assay in Japan over the past 30 years. Now most commercial calibrant plasma may be calibrated against an International Standard preparation, in order to achieve agreement of results obtained by different laboratories. However, we have never achieved satisfactory results, according to an external quality control survey regarding the fibrinogen assay. Therefore, we distributed two kinds of fibrinogen standards to be used as common calibrators, along with three plasma samples, among 183 general laboratories in Japan. The results of this collaborative study showed that the assigned value for the commercially available calibrators remained problematic. Furthermore, it was concluded that the between-laboratory variability could not be improved beyond a certain degree of standardization, even if a common calibrator was used for the Clauss-derived assay carried out by an automatic coagulometer.
Asunto(s)
Fibrinógeno/análisis , Laboratorios/normas , Calibración , Fibrinógeno/normas , Humanos , Japón , Laboratorios/estadística & datos numéricos , Plasma , Control de Calidad , Sensibilidad y EspecificidadRESUMEN
Fibrinogen plays a major role in basic coagulation tests such as prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT). These show high interlaboratory variation because of inaccurate instrumental calibration. The same is true of the fibrinogen assay, despite its being a quantitative assay. Most medical laboratories use automated coagulometers and commercially available calibration materials (calibrators) to obtain an accurate fibrinogen value, but, when checked, calibrators have been found to deviate from the assigned value. The Japan Society of Laboratory Medicine (JSLM) has identified the need for a reliable plasma fibrinogen standard. To enhance the reliability of calibrator fibrinogen values and thereby remedy the poor precision and accuracy of plasma fibrinogen testing, we undertook the preparation of a standard calibration material applicable to both the Clauss method and turbidimetric immunoassay (TIA). The calibrator was prepared from fresh human plasma by glycine precipitation and virus inactivation followed by affinity chromatography to remove contaminated plasminogen. In the resulting product, clottable fibrinogen accounted for 95% of total protein and within-run precision showed a CV of less than 1.8%. We believe the preparation will become a candidate material for laboratory and manufacturer use in Japan.
Asunto(s)
Fibrinógeno/aislamiento & purificación , Fibrinógeno/normas , Pruebas de Coagulación Sanguínea/normas , Calibración , Cromatografía de Afinidad , Fibrinógeno/análisis , Glicina , Humanos , Inmunoensayo/normas , Estándares de Referencia , EsterilizaciónRESUMEN
There is strong evidence from meta-analyses of prospective epidemiological studies that increasing plasma fibrinogen levels are associated with increasing risk of ischaemic heart disease. It has been suggested that categorization of plasma fibrinogen by thirds of the population distribution be added to cardiovascular risk prediction equations. However, the heterogeneity of plasma fibrinogen and the resulting discrepancies between commonly performed assays may lead to differences in both mean levels and distributions, and in categorizations of populations by thirds. We therefore compared three commonly performed routine fibrinogen assays in a random population sample of 1373 men and women aged 25-64 years in the fourth World Health Organization MONICA survey in north Glasgow. The two assays of clottable fibrinogen (von Clauss and prothrombin time derived) showed similar mean values and distributions, whereas the immunonephelometric assay showed lower mean values. There was significant disagreement between all three assays in categorization of thirds of population fibrinogen distribution (kappa statistic, 0.64 von Clauss versus prothrombin time derived, 0.46 von Clauss versus immunonephelometric, and 0.51 prothrombin time derived versus immunonephelometric). We conclude that further standardization of plasma fibrinogen assays is desirable for ischaemic heart disease risk stratification, and that further studies of the causes and clinical significance of discrepancies between fibrinogen assays in the general population are indicated.
Asunto(s)
Pruebas de Coagulación Sanguínea/métodos , Fibrinógeno/análisis , Inmunoensayo/métodos , Tiempo de Protrombina , Adulto , Pruebas de Coagulación Sanguínea/instrumentación , Pruebas de Coagulación Sanguínea/normas , Femenino , Fibrinógeno/normas , Humanos , Masculino , Persona de Mediana Edad , Juego de Reactivos para Diagnóstico/normas , Estándares de Referencia , Factores de Riesgo , Estadística como Asunto/métodosRESUMEN
The wide availability of fibrinogen estimations based on the prothrombin time (PT-Fg) has caused concern about the variability and clinical utility of fibrinogen assays. In a multi-centre study, we investigated fibrinogen assays using various reagents and analysers. Clauss assays generally gave good agreement, although one reagent gave 15-30% higher values in DIC and thrombolysis. Two commercial reference preparations had much lower potencies than the manufacturers declared, and plasma turbidity influenced parallelism in some Clauss assays. PT-Fg assays gave higher values than Clauss and showed calibrant dependent effects, the degree of disparity correlating with calibrant and test sample turbidity. Analyser and thromboplastin dependent differences were noted. The relationship between Clauss and PT-Fg assays was sigmoid, and the plateau of maximal PT-Fg differed by about 2 g/l between reagents. ELISA and immunonephelometric assays correlated well, but with a high degree of scatter. Antigen levels were higher than Clauss, but slightly lower than PT-Fg assays, which appeared to be influenced by degraded fibrinogen. Clauss assays are generally reproducible between centres, analysers and reagents, but PT-Fg assays are not reliable in clinical settings.
Asunto(s)
Fibrinógeno/análisis , Juego de Reactivos para Diagnóstico/normas , Pruebas de Coagulación Sanguínea/instrumentación , Pruebas de Coagulación Sanguínea/métodos , Pruebas de Coagulación Sanguínea/normas , Calibración , Fibrinógeno/normas , Humanos , Inmunoensayo , Indicadores y Reactivos/normas , Nefelometría y Turbidimetría , Variaciones Dependientes del Observador , Tiempo de Protrombina , Estándares de Referencia , Reproducibilidad de los ResultadosRESUMEN
An International Collaborative Study involving 12 laboratories in 7 different countries was undertaken in order to replace the 1st International Standard (IS) for Fibrinogen, Plasma (89/644). The candidate replacement standard was the ampouled and freeze-dried residue of solvent/detergent treated plasma and was calibrated as coded duplicates (A and B) versus the 1st IS Fibrinogen, Plasma by automated Clauss assay and by a recommended clot collection (gravimetric) assay. This latter method had been used to calibrate the 1st IS Fibrinogen, Plasma. Comparing the ratios of the potency estimates of sample A to sample B (the coded duplicates), all of the laboratories obtained a ratio within 5% of the expected value of 1.0 by automated Clauss assay, which suggests that the laboratories were able to perform this assay well. Scrutiny of the data obtained from the gravimetric assays revealed that in almost all cases the results were invalid. The results of these assays are included in this report but clearly should be treated with caution and indeed produced significantly lower mean estimates of potency than the other assay methods. The overall geometric mean of all estimates of potency of the proposed 2nd IS Fibrinogen, Plasma (98/612) is 2.19 mg/ampoule by the automated Clauss assay. These data have been presented to the Fibrinogen Sub-Committee of the Standardisation and Scientific Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH) (Washington, DC, August 1999), which recommended the establishment of 98/612 as the 2nd IS Fibrinogen, Plasma. This report has been presented to the Expert Committee on Biological Standardisation of the World Health Organisation (ECBS-WHO) at their 1999 session and 98/612 was established as the 2nd IS Fibrinogen, Plasma with a potency of 2.2 mg/ampoule.